

New liver cancer treatment could save millions of patients

Scientists have discovered that the combination of atezolizumab and bevacizumab prolonged survival compared with standard-of-care sorafenib for liver cancer patients who had not received prior systemic therapy. The Roche-developed drugs reduced the risk of disease progression or death by 42% compared with sorafenib in liver cancer patients. The combined therapy is administered via vein injections on the first day of each 21-day cycle.